Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function
Cd. Frances et al., Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function, ARCH IN MED, 160(17), 2000, pp. 2645-2650
Citations number
25
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Context: Angiotensin-converting enzyme (ACE) inhibitors have been shown to
decrease mortality in patients with myocardial infarction and depressed lef
t ventricular function, but physicians may be reluctant to prescribe ACE in
hibitors to patients with concomitant renal insufficiency.
Objective: To evaluate whether patients with depressed left, ventricular ej
ection fraction following acute myocardial infarction have a similar reduct
ion in mortality from ACE inhibitors regardless of their renal function.
Design: Retrospective cohort study using medical record data.
Setting: All nonfederal acute care hospitals.
Patients: A cohort of 20902 Medicare beneficiaries aged 65 years and older
directly admitted to the hospital from February 1, 1994, through July 30, 1
995, and with a documented left ventricular ejection fraction of less than
40% measured by echocardiography, radionuclide scintigraphy, or angiography
following a confirmed acute myocardial infarction.
Main Outcome Measures: One-year survival for patients who received or who d
id not receive an ACE inhibitor at hospital discharge, stratified by the pa
tient's level of renal function.
Results: For the entire cohort, the receipt of an ACE inhibitor on hospital
discharge was associated with greater 1-year survival (hazards ratio, 0.84
; 95% confidence interval, 0.77-0.91) after adjusting for patient demograph
ic characteristics, comorbidity, severity of illness (including left ventri
cular ejection fraction), and the receipt of other therapies. In stratified
models, the receipt of an ACE inhibitor was associated with a 37% (16%-52%
) lower mortality for patients who had poor renal function (serum creatinin
e level,<265 mu mol/L [<3 mg/dL]) and a 16% (8%-23%) lower mortality for pa
tients who had better renal function. Use of aspirin therapy attenuated the
benefit of ACE inhibitors in patients with poor renal function.
Conclusions: Moderate renal insufficiency should not be considered a contra
indication to the use of ACE inhibitors in patients with depressed left ven
tricular ejection fraction following myocardial infarction. Use of aspirin
therapy may attenuate the benefit of ACE inhibitors in patients with high s
erum creatinine levels; therefore, further studies are needed to determine
whether treatment with aspirin, alternative antiplatelet agents, or anticoa
gulation is indicated for these patients.